Abbott Laboratories stock edges higher as investors digest tax-related insider transaction and cyber security update

Abbott Laboratories (ISIN US0028241000) stock is trading around 109.21 USD as of September 4, 2026, according to market data from Cboe, modestly above its fifty day moving average of 104.14 USD and its 200 day moving average of 100.06 USD, indicating a steadily improving trend in recent weeks as investors continue to price in the company’s earnings profile and balance sheet strength.

Insider tax transaction and cyber security context

According to a Form 4 filing summarized by Stock Titan, executive vice president and chief financial officer Philip P. Boudreau used 388 Abbott Laboratories common shares on September 1, 2026 at a price of 110.36 USD per share to cover exercise price or tax liability related to equity awards rather than selling shares in the open market, leaving him with 70,784 shares in direct ownership.

This type of tax-related share disposal is generally interpreted as a technical transaction rather than a directional bet on Abbott Laboratories stock, which helps explain why the share price remains supported near 109.21 USD as of September 4, 2026 instead of reacting sharply to the Form 4 disclosure.

Analyst consensus and earnings growth backdrop

MarketBeat data compiled as of September 4, 2026 shows that Abbott Laboratories stock opened at 108.81 USD on the New York Stock Exchange on the latest trading day, with an analyst consensus rating described as Moderate Buy and an average target price of 119.50 USD, implying upside of about 10.3% compared with the current level near 108.81 USD and underlining continued confidence in the company’s earnings trajectory.

Financial information summarized by Zonebourse indicates that Abbott Laboratories most recently reported group net income of 7.07 billion in its latest fiscal year, up from 6.93 billion in the previous fiscal year, a year-on-year increase of about 2.0% that forms part of a longer series of profit expansion after a pandemic-related dip.

The same overview shows that Abbott’s one-year revenue growth rate in that latest fiscal year stood at 24.47%, compared with only 1.34% in the preceding year and a decline of 8.12% in the year before that, highlighting a strong rebound in sales momentum that has helped support margins and underpins the Moderate Buy consensus on Abbott Laboratories stock.

Cyber security incident seen as manageable

In the broader risk context, a Reuters factbox on cyber attacks against United States companies, republished by Investing.com, notes that in July Abbott Laboratories reported unauthorized access to a limited number of internal systems in its cancer diagnostics business and a potential breach of its LabCentral portal, but indicated that it did not expect a material impact on operations, customers or financial results.

For investors, this assessment is important because it suggests that while cyber security remains a structural risk factor for healthcare companies, the specific July incident described by Abbott is unlikely to derail the company’s earnings trajectory or materially change the Moderate Buy consensus currently supporting Abbott Laboratories stock.

Representative Abbott product and segment exposure

One of Abbott Laboratories’ key consumer-facing franchises is its nutrition business, which includes widely known brands such as Pedialyte oral rehydration solutions used to help prevent dehydration in children and adults; this segment contributes meaningfully to Abbott’s diversified revenue base alongside diagnostics, medical devices and established pharmaceuticals, helping to smooth earnings across economic cycles.

Abbott Laboratories stock level and market context

As of September 4, 2026, quote data from Cboe compiled by Marketscreener show Abbott Laboratories stock at 109.21 USD, with a five-day performance of plus 0.43% and a year-to-date decline of 13.19%, indicating that while the shares have recovered modestly in the very short term, they still trade below levels seen at the start of the year, leaving room for a potential catch-up if earnings and guidance remain on track.